Cardiff Oncology (CRDF) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price targets for Cardiff Oncology's shares. Their CRDF share price forecasts range from $5.00 to $14.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 381.9% from the stock's current price.
View analysts price targets for CRDF or view top-rated stocks among Wall Street analysts.

Cardiff Oncology's stock was trading at $1.40 on January 1st, 2023. Since then, CRDF shares have increased by 18.6% and is now trading at $1.66.
View the best growth stocks for 2023 here.

Cardiff Oncology saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 542,300 shares, a decline of 12.1% from the April 30th total of 616,900 shares. Based on an average daily volume of 198,500 shares, the short-interest ratio is currently 2.7 days.
View Cardiff Oncology's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CRDF earnings forecast.

Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.08 million. Cardiff Oncology had a negative net margin of 9,862.78% and a negative trailing twelve-month return on equity of 35.70%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF."

Cardiff Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.70%), Citigroup Inc. (1.46%), Assenagon Asset Management S.A. (0.88%), Renaissance Technologies LLC (0.74%), Two Sigma Advisers LP (0.32%) and Blair William & Co. IL (0.29%). Insiders that own company stock include Gary W Pace, James E Levine, John P Brancaccio, Lale White, Mark Erlander, Renee P Tannenbaum, Rodney S Markin and Vicki Kelemen.
View institutional ownership trends.

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRDF stock can currently be purchased for approximately $1.66.

Cardiff Oncology (NASDAQ:CRDF) has a market capitalization of $74.17 million and generates $390,000.00 in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The official website for the company is cardiffoncology.com. The company can be reached via phone at (858) 952-7570 or via email at ir@cardiffoncology.com.